Do you know what a biologic is? AMRI's Organichem manufactures small molecules, not biologics, which are protein-based drugs such as monoclonal antibodies. How does BMS's decision to build a biologics plant have anything to do with AMRI's business strategy?
The fact is, the outsourcing business is crushingly difficult these days. Generics are manufactured on very thin margins. AMRI doesn't have compounds in Phase III, and mentions nothing about nanotechnology in any of its press releases or analyst calls. Where do you get your "information"?
You have to admire the spin Bashers use. �it looks as though manufacturing pharmaceuticals in America is back in favor�. That means that BMS is building a cGMP/FDA approved facility in America and not India/China�.. The logic that this is encouraging for the US industry is obvious. How can you have �sell� with the global and platform expansion underway at AMRI.